Search

Hoon J. Chung

Examiner (ID: 296, Phone: (571)272-4059 , Office: P/2474 )

Most Active Art Unit
2474
Art Unit(s)
4173, 2474, 2419, 2416, CQIC
Total Applications
707
Issued Applications
575
Pending Applications
11
Abandoned Applications
123

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18020594 [patent_doc_number] => 20220372093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => TGF-Beta Polypeptides [patent_app_type] => utility [patent_app_number] => 17/722328 [patent_app_country] => US [patent_app_date] => 2022-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722328 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/722328
TGF-b polypeptides Apr 15, 2022 Issued
Array ( [id] => 17913242 [patent_doc_number] => 20220315637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 17/717740 [patent_app_country] => US [patent_app_date] => 2022-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717740 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/717740
Methods of making and using extracellular domain-based chimeric proteins Apr 10, 2022 Issued
Array ( [id] => 17929805 [patent_doc_number] => 20220324930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/717783 [patent_app_country] => US [patent_app_date] => 2022-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27456 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717783 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/717783
Activatable interleukin 12 polypeptides and methods of use thereof Apr 10, 2022 Issued
Array ( [id] => 19265393 [patent_doc_number] => 20240209092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => COMBINATION THERAPIES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/554870 [patent_app_country] => US [patent_app_date] => 2022-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52640 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554870 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/554870
COMBINATION THERAPIES FOR TREATING CANCER Apr 10, 2022 Pending
Array ( [id] => 18013312 [patent_doc_number] => 11505594 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Anti-VEGF protein compositions and methods for producing the same [patent_app_type] => utility [patent_app_number] => 17/711723 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 86 [patent_no_of_words] => 67818 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711723 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/711723
Anti-VEGF protein compositions and methods for producing the same Mar 31, 2022 Issued
Array ( [id] => 20386595 [patent_doc_number] => 12486312 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Immunomodulatory proteins with tunable affinities [patent_app_type] => utility [patent_app_number] => 17/707511 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 44853 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 218 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707511 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/707511
Immunomodulatory proteins with tunable affinities Mar 28, 2022 Issued
Array ( [id] => 19265392 [patent_doc_number] => 20240209091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => METHODS FOR TREATING CANCER USING ANTI-CTLA4 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/553043 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553043 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/553043
METHODS FOR TREATING CANCER USING ANTI-CTLA4 ANTIBODIES Mar 27, 2022 Pending
Array ( [id] => 19201492 [patent_doc_number] => 20240173391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => THERAPEUTIC COMBINATION FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/552383 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37420 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552383 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/552383
THERAPEUTIC COMBINATION FOR TREATING CANCER Mar 24, 2022 Pending
Array ( [id] => 19248749 [patent_doc_number] => 20240199736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/552113 [patent_app_country] => US [patent_app_date] => 2022-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552113 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/552113
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER Mar 23, 2022 Pending
Array ( [id] => 17720443 [patent_doc_number] => 20220213163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => IL-2 CHIMERIC PROTEINS FOR IMMUNOSUPPRESSION [patent_app_type] => utility [patent_app_number] => 17/701108 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701108 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/701108
IL-2 CHIMERIC PROTEINS FOR IMMUNOSUPPRESSION Mar 21, 2022 Abandoned
Array ( [id] => 17720502 [patent_doc_number] => 20220213222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => PREVENTION AND TREATMENT OF TYPE-1 DIABETES USING AGONISTS OF THE (NA++K+)-ATPASE [patent_app_type] => utility [patent_app_number] => 17/701626 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701626 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/701626
Prevention and treatment of type-1 diabetes using agonists of the (NA Mar 21, 2022 Issued
Array ( [id] => 17895442 [patent_doc_number] => 20220305104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => METHODS OF TREATING ATOPIC DERMATITIS [patent_app_type] => utility [patent_app_number] => 17/696028 [patent_app_country] => US [patent_app_date] => 2022-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17696028 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/696028
Methods of treating atopic dermatitis Mar 15, 2022 Issued
Array ( [id] => 17734720 [patent_doc_number] => 20220220179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => FUSION PROTEIN COMPRISING IL13 [patent_app_type] => utility [patent_app_number] => 17/693956 [patent_app_country] => US [patent_app_date] => 2022-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -223 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17693956 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/693956
Fusion protein comprising IL13 Mar 13, 2022 Issued
Array ( [id] => 20336505 [patent_doc_number] => 20250340625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2, OR FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 18/556651 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556651 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/556651
ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2, OR FRAGMENT THEREOF Mar 9, 2022 Pending
Array ( [id] => 17867099 [patent_doc_number] => 20220289834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody [patent_app_type] => utility [patent_app_number] => 17/691219 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17691219 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/691219
Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody Mar 9, 2022 Pending
Array ( [id] => 19809518 [patent_doc_number] => 12240889 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Decoy cytokine receptor [patent_app_type] => utility [patent_app_number] => 17/687554 [patent_app_country] => US [patent_app_date] => 2022-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 75 [patent_no_of_words] => 29462 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17687554 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/687554
Decoy cytokine receptor Mar 3, 2022 Issued
Array ( [id] => 19491647 [patent_doc_number] => 12110343 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-08 [patent_title] => Anti-plasma kallikrein antibodies [patent_app_type] => utility [patent_app_number] => 17/684460 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 5 [patent_no_of_words] => 13930 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684460 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/684460
Anti-plasma kallikrein antibodies Mar 1, 2022 Issued
Array ( [id] => 17672711 [patent_doc_number] => 20220185878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/684907 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684907 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/684907
Biopharmaceutical compositions Mar 1, 2022 Issued
Array ( [id] => 17830125 [patent_doc_number] => 20220267429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 17/684305 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684305 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/684305
Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders Feb 28, 2022 Issued
Array ( [id] => 19425078 [patent_doc_number] => 12084481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => HV1 modulators and uses [patent_app_type] => utility [patent_app_number] => 17/684346 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 35 [patent_no_of_words] => 21839 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17684346 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/684346
HV1 modulators and uses Feb 28, 2022 Issued
Menu